Hvivo signs €7.3m contract to test common cold treatment
Study will evaluate the effect of the antiviral candidate on viral load, safety and tolerability against HRV infection in healthy volunteers
Hvivo, the Irish pharmaceutical services company founded by Irish businessman Cathal Friel, has signed a £6.3 million (€7.28 million) contract to test a potential treatment for the common cold.
The agreement is with a biotechnology client to test its antiviral candidate using the Hvivo Human Rhinovirus (HRV\) Human Challenge Study Model.
The Phase 2a randomised, double-blinded placebo-controlled human challenge trial is planned to take place at the company’s new specialist state-of-the-art quarantine facilities in Canary ...